Cytoreductive debulking surgery among patients with neuroendocrine liver metastasis: a multi-institutional analysis

Published on Apr 1, 2017in Hpb3.401
· DOI :10.1016/J.HPB.2017.08.039
Aslam Ejaz34
Estimated H-index: 34
(Johns Hopkins University),
Bradley N. Reames19
Estimated H-index: 19
(Johns Hopkins University)
+ 7 AuthorsTimothy M. Pawlik118
Estimated H-index: 118
(OSU: Ohio State University)
Sources
Abstract
Abstract Background Management of neuroendocrine liver metastasis (NELM) in the setting of unresectable disease is poorly defined and the role of debulking remains controversial. The objective of the current study was to define outcomes following non-curative intent liver-directed therapy (debulking) among patients with NELM. Methods 612 patients were identified who underwent liver-directed therapy of NELM from a multi-institutional database. Outcomes were stratified according to curative (R0/R1) versus non-curative ≥ 80% debulking (R2). Results 179 (29.2%) patients had an R2/debulking procedure. Patients undergoing debulking more commonly had more aggressive high-grade tumors (R0/R1: 12.8% vs. R2: 35.0%; P  Conclusion Debulking operations for NELM provided reasonable long-term survival. Hepatic debulking for patients with NELM is a reasonable therapeutic option for patients with grossly unresectable disease that may provide a survival benefit.
📖 Papers frequently viewed together
272 Citations
201724.80JAMA Oncology
8 Authors (Arvind Dasari, ..., James C. Yao)
984 Citations
22 Citations
References16
Newest
#1Aslam EjazH-Index: 34
#2Brad N. ReamesH-Index: 1
Last. Timothy M. Pawlik (OSU: Ohio State University)H-Index: 118
view all 10 authors...
Introduction Management of neuroendocrine liver metastasis (NELM) in the presence of extrahepatic disease (EHD) is controversial. We sought to examine outcomes of patients undergoing liver-directed therapy (resection, ablation, or both) for NELM in the presence of EHD using a large international cohort of patients. Methods 612 patients who underwent liver-directed therapy were identified from eight institutions. Postoperative outcomes, as well as and overall (OS) were compared among patients wit...
8 CitationsSource
#1Heather A. Farley (OHSU: Oregon Health & Science University)H-Index: 2
#2Rodney F. Pommier (OHSU: Oregon Health & Science University)H-Index: 38
Neuroendocrine tumors are rare and slow-growing malignancies that commonly metastasize to the liver, resulting hormonal syndromes and death from liver failure. Surgical consultation and liver debulking are key components in management. Traditional surgical resection guidelines do not apply to these tumors as with other cancers. Surgical resection has shown survival benefit even in the event of an incomplete resection. Ablation may be used as an adjunct to resection or in patients who are not can...
37 CitationsSource
#1Gaya Spolverato (Johns Hopkins University)H-Index: 51
#2Fabio Bagante (Johns Hopkins University)H-Index: 27
Last. Timothy M. Pawlik (Johns Hopkins University)H-Index: 118
view all 8 authors...
Abstract Background A large subset of patients with neuroendocrine liver metastasis (NELM) is symptomatic at the time of presentation. In addition to improving survival, treatment of NELM seeks to provide palliation of symptoms. However, data on health-related quality of life (QoL) are uncommon. We sought to define patient-reported QoL after treatment of NELM. Methods Patients who underwent treatment of NELM at Johns Hopkins Hospital between 1998 and 2013 and who were alive as of March 2014 were...
24 CitationsSource
#1Amanda N. Graff-Baker (OHSU: Oregon Health & Science University)H-Index: 2
#2David Sauer (OHSU: Oregon Health & Science University)H-Index: 12
Last. Rodney F. Pommier (OHSU: Oregon Health & Science University)H-Index: 38
view all 4 authors...
Background Cytoreduction of carcinoid liver metastases typically aims for ≥90% debulking in patients without extrahepatic disease. Data on the impact of less-restrictive resection criteria and other clinical and tumor-specific factors on outcomes are limited. Methods Records of carcinoid patients undergoing liver debulking from 2007 to 2011 were reviewed. Debulking threshold was 70%, extrahepatic disease did not preclude cytoreduction, and positive margins were allowed. Kaplan-Meier liver progre...
64 CitationsSource
#1J. Philip Boudreaux (University Medical Center New Orleans)H-Index: 15
#2Yi-Zarn Wang (University Medical Center New Orleans)H-Index: 18
Last. Eugene A. Woltering (University Medical Center New Orleans)H-Index: 42
view all 8 authors...
Background Well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract are rare, slow-growing neoplasms. Clinical outcomes in a group of stage IV, well-differentiated patients with NETs with small bowel primaries undergoing cytoreductive surgery and multidisciplinary management at a single center were evaluated. Study Design The charts of 189 consecutive patients who underwent surgical cytoreduction for their small bowel NETs were reviewed. Information on the extent of disease...
30 CitationsSource
#1Louis de Mestier (University of Paris)H-Index: 17
#2Cindy NeuzilletH-Index: 20
Last. Philippe RuszniewskiH-Index: 79
view all 6 authors...
Peritoneal carcinomatosis is a well-known factor of poor prognosis in patients with digestive adenocarcinomas. Peritoneal dissemination may also occur in midgut well-differentiated neuroendocrine tumors, but its influence on survival is ill-defined. We report here the history of a 64-year-old woman who had a neuroendocrine tumor of the cecum with multiple synchronous metastases in the liver and diffuse peritoneal carcinomatosis. She underwent surgical resection of the primary tumor and cytoreduc...
7 CitationsSource
#1Evan S. Glazer (University of Texas MD Anderson Cancer Center)H-Index: 19
#2Jennifer F. Tseng (UMMS: University of Massachusetts Medical School)H-Index: 57
Last. Steven A. Curley (University of Texas MD Anderson Cancer Center)H-Index: 98
view all 9 authors...
Abstract Background Surgical cytoreduction and endocrine blockade are important options for care for neuroendocrine liver metastases. We investigated the long-term survival of patients surgically treated for hepatic neuroendocrine metastases. Methods Patients ( n = 172) undergoing operations for neuroendocrine liver metastases from any primary were identified from a prospective liver database. Recorded data and medical record review were used to analyse the type of procedure, length of hospital ...
155 CitationsSource
#1David S. Klimstra (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 145
#2Irvin R. ModlinH-Index: 2
Last. Saul SusterH-Index: 82
view all 5 authors...
Neuroendocrine tumors (NETs) arise in most organs of the body and share many common pathologic features. However, a variety of different organ-specific systems have been developed for nomenclature, grading, and staging of NETs, causing much confusion. This review examines issues in the pathologic assessment of NETs that are common among primaries of different sites. The various systems of nomenclature are compared along with new proposal for grading and staging NETs. Although differences persist...
828 CitationsSource
#1Skye C. Mayo (Johns Hopkins University)H-Index: 25
#2Mechteld C. de Jong (Johns Hopkins University)H-Index: 23
Last. Timothy M. Pawlik (Johns Hopkins University)H-Index: 118
view all 21 authors...
Background Management of neuroendocrine tumor liver metastasis (NELM) remains controversial, with some advocating an aggressive surgical approach while others have adopted a more conservative strategy. We sought to define the efficacy of the surgical management of NELM in a large multicenter international cohort of patients.
298 CitationsSource
#1Anthony J. Chambers (TBCC: Tom Baker Cancer Centre)H-Index: 13
#2Janice L. Pasieka (TBCC: Tom Baker Cancer Centre)H-Index: 34
Last. Otto Rorstad (TBCC: Tom Baker Cancer Centre)H-Index: 12
view all 4 authors...
Background Metastatic neuroendocrine tumors (NETs) can present with complications of gastrointestinal tract obstruction or ischemia and carcinoid syndrome (CS). The purpose of this study was to assess whether aggressive surgical intervention of metastatic NETs provides effective palliation from these symptoms. Methods Sixty-six patients with metastatic gastrointestinal tract NETs that presented with either CS and/or obstructive symptoms were retrospectively reviewed. All patients were managed ac...
84 CitationsSource
Cited By21
Newest
#1R.C. Pickens (Carolinas Medical Center)H-Index: 3
#2Jesse K. Sulzer (Carolinas Medical Center)H-Index: 3
Last. David A. Iannitti (Carolinas Medical Center)H-Index: 30
view all 10 authors...
Background and Purpose: Operative microwave ablation (MWA) is a safe modality for treating hepatic tumors. The aim of this study is to present our 10-year, single-center experience of operative MWA for neuroendocrine liver metastases (NLM). Methods: A single-institution retrospective review of patients who underwent operative MWA for NLM was performed (2008-2018). Demographics, primary tumor site, operative approach, combined surgical operations, and carcinoid symptoms were recorded. Clinical ou...
Source
#1Yashwant Sakaray (PGIMER: Post Graduate Institute of Medical Education and Research)H-Index: 2
#2Kishore Abuji (PGIMER: Post Graduate Institute of Medical Education and Research)
Last. Santhosh Irrinki (PGIMER: Post Graduate Institute of Medical Education and Research)H-Index: 3
view all 4 authors...
Primary retroperitoneal neuroendocrine tumours (NETs) are extremely rare, and many a times, these are metastatic lesions with known or unknown primary location, most commonly arising from the stomach, duodenum, small intestine and rectum. NETs arising from the duodenum are more commonly seen in the first part of the duodenum followed by the second part. The incidence is increasing because of easy accessibility to endoscopies and cross-sectional imaging. In NETs, lymph node (LN) metastasis occurs...
Source
#1Tomoyuki HishidaH-Index: 33
#2Kyohei MasaiH-Index: 8
Last. Hisao Asamura (Keio: Keio University)H-Index: 86
view all 5 authors...
Debulking surgery, also called cytoreductive surgery, is a resection of the tumor as much as possible and an intended incomplete resection for unresectable malignant tumors. Since the most important principle in surgical oncology is complete R0 resection, debulking surgery goes against the basic principle and obscures the concept of operability. However, debulking surgery has been advocated for various types of advanced malignant tumors, including gynecological cancers, urological cancers, gastr...
Source
#1Taku Aoki (Dokkyo Medical University)H-Index: 38
#2Keiichi Kubota (Dokkyo Medical University)H-Index: 60
Last. Norihiro KokudoH-Index: 97
view all 14 authors...
Background/purpose Hepatic resection is considered the treatment of choice for neuroendocrine liver metastases (NELM). However, the safety and efficacy of resection have not been fully evaluated using a large cohort. The aim of the present study was to collect real-world data regarding hepatic resections for NELM. Methods A retrospective, multicenter survey was conducted. The background characteristics of patients undergoing an initial hepatic resection for NELM, the operative details, pathologi...
Source
Background Primary extra-gastrointestinal stromal tumors (E-GIST) of the liver are rare. The clinical presentation may range from asymptomatic to bleeding or manifestations of mass effect. Oncologic surgery followed by adjuvant therapy with imatinib is the standard of care. However, under specific circumstances, a cytoreductive approach may represent a therapeutic option. We describe herein the case of an 84-year-old woman who presented with a tender, protruding epigastric mass. Abdominal comput...
Source
Neuroendocrine neoplasms (NEN) are frequently characterized by a high propensity for metastasis to the liver, which appears to be a dominant site of distant-stage disease, affecting quality of life and overall survival. Liver surgery with the intention to cure is the treatment of choice for resectable neuroendocrine liver metastases (NELM), aiming to potentially prolong survival and ameliorate hormonal symptoms refractory to medical control. Surgical resection is indicated for patients with NELM...
2 CitationsSource
#1Diamantis I. Tsilimigras (The Ohio State University Wexner Medical Center)H-Index: 21
#2J. Madison Hyer (The Ohio State University Wexner Medical Center)H-Index: 16
Last. Timothy M. Pawlik (The Ohio State University Wexner Medical Center)H-Index: 118
view all 9 authors...
BACKGROUND The objective of this study was to analyze whether primary tumor resection (PTR) among patients with stage IV gastrointestinal neuroendocrine tumor (GI-NET) and unresected metastases was associated with improved outcomes. METHODS Patients diagnosed with stage IV GI-NETs were identified in the linked SEER-Medicare database from 2004 to 2015. Overall survival (OS) of patients who did versus did not undergo PTR was examined using bivariate and multivariable cox regression analysis as wel...
Source
#1Adrian J. Gonzalez-Aguirre (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 7
#2Etay Ziv (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 11
Source
Pancreatic neuroendocrine tumors (PNET) are a heterogeneous group of neoplasms that vary in their clinical presentation, behavior and prognosis. The most common site of metastasis is the liver. Surgical resection of neuroendocrine liver metastases (NELM) is thought to afford the best long-term outcomes when feasible. Initial preoperative workup should include surveillance for carcinoid syndrome, screening for evidence of liver insufficiency, and performance of imaging specific to neuroendocrine ...
1 CitationsSource
#1Zuyi Ma (Academy of Medical Sciences, United Kingdom)H-Index: 4
#2Yuanfeng Gong (Academy of Medical Sciences, United Kingdom)H-Index: 2
Last. Baohua Hou (Academy of Medical Sciences, United Kingdom)H-Index: 13
view all 11 authors...
Pancreatic neuroendocrine tumors (pNETs) are a heterogeneous group of tumors with complicated treatment options that depend on pathological grading, clinical staging, and presence of symptoms related to hormonal secretion. With regard to diagnosis, remarkable advances have been made: Chromogranin A is recommended as a general marker for pNETs. But other new biomarker modalities, like circulating tumor cells, multiple transcript analysis, microRNA profile, and cytokines, should be clarified in fu...
5 CitationsSource